Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature.
Immune-related adverse events
Ipilimumab
Nivolumab
Primary adrenal insufficiency
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
31
03
2020
accepted:
31
03
2020
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
epublish
Résumé
As the indications and clinical use of immune checkpoint inhibitors increase, it is expected that we will face some of their less frequently reported complications. Primary adrenal insufficiency is one of them, and given its unspecific symptoms and potentially serious consequences, it is important to have a high degree of clinical suspicion. We present 3 cases and a review of the literature concerning its main clinical characteristics, diagnostics, and management.
Identifiants
pubmed: 32595473
doi: 10.1159/000507652
pii: cro-0013-0621
pmc: PMC7315192
doi:
Types de publication
Case Reports
Langues
eng
Pagination
621-626Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Alex Renner: travel, accommodations, expenses: Roche. Suraj Samtani: travel, accommodations, expenses: Roche. Mauricio Burotto: consulting: Genentech, Bristol-Myers Squibb, Merck, Astrazeneca. Carlos Rojas: honoraria: Bristol-Myers Squibb, Astrazeneca, Roche. No other potential conflicts of interest were reported.
Références
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
JAMA Oncol. 2018 Feb 1;4(2):173-182
pubmed: 28973656
J Oncol Pract. 2018 Apr;14(4):247-249
pubmed: 29517954
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Immunother. 2007 Nov-Dec;30(8):825-30
pubmed: 18049334
Cancer. 2017 Jun 1;123(11):1904-1911
pubmed: 28241095
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044
Lancet Diabetes Endocrinol. 2013 Nov;1(3):e15
pubmed: 24622375
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
J Clin Endocrinol Metab. 2013 Apr;98(4):1361-75
pubmed: 23471977
Nat Rev Endocrinol. 2017 Apr;13(4):195-207
pubmed: 28106152
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Endocrinol Diabetes Metab Case Rep. 2016;2016:
pubmed: 27857838
Clin Nucl Med. 2015 Nov;40(11):e518-9
pubmed: 26164177
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759